This content was written and submitted by the supplier. It has only been modified to comply with this publication’s space and style.
The conference will detail management experience, lessons learned, findings, and insights on cGMP bioprocessing facilities including new plans for reduced capital and operating costs; successful models for people and materials flow; implementation strategies for modular and disposable technologies; capacity planning approaches for mixed-use, multiproduct facilities; plans that maximize flexibility and speed to market; advances in MEP and processing equipment and more.
Speakers will include representatives from Fraunhofer USA, on their first-of-its-kind cGMP facility for plant-based protein production that does not require large-scale culturing or fermentation processes; Statens Serum Institute of Copenhagen, Denmark, an international research, production and service enterprise involved in vaccine and biologics development and diagnostic services; and Texas A&M's 155,000-sf National Center for Therapeutics Manufacturing (NCTM), which has the capacity for developing and producing multiple biological products using multiple production technologies.
For more information about Bioprocessing Facilities 2011 click here.
Speakers will include representatives from Fraunhofer USA, on their first-of-its-kind cGMP facility for plant-based protein production that does not require large-scale culturing or fermentation processes; Statens Serum Institute of Copenhagen, Denmark, an international research, production and service enterprise involved in vaccine and biologics development and diagnostic services; and Texas A&M's 155,000-sf National Center for Therapeutics Manufacturing (NCTM), which has the capacity for developing and producing multiple biological products using multiple production technologies.
For more information about Bioprocessing Facilities 2011 click here.
Companies in this article
